*Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas; †The Daniel and Gloria Blumenthal Cancer Center, Paramus, New Jersey, and the Division of Thoracic Surgery, The Valley Hospital, Ridgewood, New Jersey; ‡Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, Bethesda, Maryland; and §Department of Surgery, Division of Thoracic Surgery, Yale University School of Medicine, New Haven, Connecticut.
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S119-24. doi: 10.1097/JTO.0000000000000296.
Measuring tumor response to chemotherapy is important for both clinical decision-making and for multi-institutional studies. Thymoma tends to spread along the pleura: a challenge for accurate tumor measurement. Inaccurate and inconsistent tumor measurements often compromise results from clinical trials that are dependent on identifying response rate and progression-free survival. In this article, we sought to provide a practical guide on how to measure thymoma by the International Thymic Malignancy Interest Group's recommendations for standard outcome measures. The aim of this article is to clarify this measuring technique, lead to consistency between institutions, and minimize intra- and interobserver variability.
测量肿瘤对化疗的反应对于临床决策和多机构研究都很重要。胸腺瘤往往沿着胸膜扩散：这给准确的肿瘤测量带来了挑战。不准确和不一致的肿瘤测量结果常常会影响临床试验的结果，因为这些临床试验依赖于确定反应率和无进展生存期。在本文中，我们试图根据国际胸腺癌研究组（International Thymic Malignancy Interest Group）的标准预后指标建议，提供一种实用的胸腺瘤测量方法指南。本文的目的是阐明这种测量技术，促进机构之间的一致性，并最大限度地减少观察者内和观察者间的变异性。
